Healthcare Regulation (HIPAA)

For decades, patients with advanced chondrosarcoma had no options. Now, a new drug's journey to the FDA offers a lifeline and a lesson in medical neglect.

An AI named Grace is now collecting hospital bills more effectively and with higher patient satisfaction than humans. Is this the future of service or a step too far?

A new partnership between AI consultancy Toboggan Labs and research giant Mila aims to solve a critical problem: turning cutting-edge AI into real-world medical tools.

Lexeo Therapeutics finalizes a pivotal trial for its Friedreich ataxia gene therapy, leveraging a novel trial design and accelerated FDA pathway.

A missed clinical trial endpoint is often the end. For Elicio Therapeutics, a deeper data dive reveals a potential path forward for a high-need patient group.

While biopharma braces for Medicare price negotiations, Halozyme claims immunity. Is its tech-licensing model the new blueprint for resilience or just a loophole?

One company's focus on convenience just earned it top marks. We explore how streamlined ordering and tech-savvy verification are reshaping the vision care industry.

A Dutch biotech is in late-stage trials for nizubaglustat, a drug targeting rare, fatal neurological disorders. A look at the science, strategy, and hope.

A massive 15,000-patient study on an existing therapy could upend respiratory care, combat antibiotic resistance, and deliver a bottom-line windfall.

A breakthrough publication identifies a novel protein, LanCL1, as a key target for neuropathic pain, validating a new class of drugs for millions of sufferers.

Sanofi's latest FDA nod for Tzield isn't just a new drug approval; it's a strategic shift from symptom management to disease modification in Type 1 Diabetes.

A major data breach at Ohio Living exposes sensitive patient and employee data, echoing a past failure and signaling a deepening crisis for the entire sector.

A Chicago jury's landmark verdict reveals how a single day's delay can lead to a lifetime of paralysis, questioning the very fabric of patient safety.

A silent barrier in diabetes care, 'clinical inertia,' leaves patients at risk. New research shows how empowering pharmacists with targeted education can turn the tide.

EXL's new Gold Tier status with Databricks isn't just a partnership upgrade; it's a strategic move to solve AI's biggest business problem: data governance.

A new partnership between isolved and PosterElite aims to automate labor law compliance, a complex and costly administrative headache for employers in the modern era.

Echo IQ partners with Mayo Clinic to test its AI for cardiac risk in cancer patients, a key move for validation in the burgeoning cardio-oncology sector.

MBX Biosciences' new one-year data for canvuparatide isn't just a clinical win; it's a calculated move to dominate a billion-dollar market left vacant.

Jazz Pharma's lung cancer drug Zepzelca fails a key trial, raising regulatory questions. Yet its strength in another setting reveals a complex drug development system.

While firms spend billions on tech, a new book argues the biggest data breaches stem from leadership gaps and process failures. Is your boardroom the real front line?